This project explores a new model of care that enhances survivorship care planning and promotes health for men with localized prostate cancer transitioning to post-treatment selfmanagement. Survivorship care planning is important for patients with prostate cancer because of its high incidence rate in the U.S., the frequent occurrence of treatment-related side effects, and reduced quality of life for both men and their partners. A key component of comprehensive survivorship care planning is survivorship care plans (SCPs), documents that summarize cancer diagnosis, treatment, and plans for follow-up care. However, research concerning the effectiveness of survivorship care plans (SCPs) on patient outcomes or health service use has thus far been inconclusive. SCPs that are tailored to individual patients' needs for information and care may improve effectiveness. In this study, we will examine the feasibility of an Enhanced Survivorship Care Plan (ESCP) that integrates a symptom self-management mHealth program called Prostate Cancer Education and Resources for Couples (PERC) into the existing standardized SCP. We will use a two-group randomized controlled pretest-posttest design and collect data at baseline (T1) and 4 months later (T2) among 50 patients completing initial treatment for localized prostate cancer and their partners. The specific aims are: Aim 1: Examine the feasibility of delivering ESCPs (as assessed by recruitment, enrollment, and retention rates, program satisfaction with the ESCP, and perceived ease of use of the ESCP). We will use mixed methods to achieve this aim. Aim 2: Estimate the magnitude of benefit of ESCPs. We hypothesize that, compared with the standardized SCP users, the ESCP users will report: (1) greater improvement in their primary outcomes of quality of life (overall, physical, emotional, and social quality of life); (2) greater improvement in secondary outcomes (reduction in negative appraisals and improvement in self-efficacy, social support, and health behaviors to manage symptoms); and (3) fewer visits to post-treatment care services from T1 (baseline) to T2 (four-month followup). The results from this study will help design a definitive randomized trial to test the efficacy of the ESCPs.